Carlos Martín-Alonso

Carlos Martín-Alonso

Auto-generated profile, based on publicly available information

Carlos Martín-Alonso

Biochemistry and Molecular Genetics Department, Biomedical Diagnostic Center (CDB), Hospital Clínic de Barcelona , 08036 Barcelona, Catalonia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2026 in European Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
ABAleix Borja Fabregat Bolufer
Aleix Borja Fabregat Bolufer
CMCarlos Martín-Alonso
Carlos Martín-Alonso
AEAlba Escolà-Rodríguez
Alba Escolà-Rodríguez
Manuel Morales-RuizManuel Morales-Ruiz
Manuel Morales-Ruiz
Spanish pharmacovigilance alerts have highlighted vitamin D overdosing. We retrospectively analysed adult serum 25(OH)D results from a Barcelona tertiary hospital (2020-2025), measured using a VDSCP-certified immunoassay. For results >100 ng/mL (250 nmol/L), concomitant calcium, phosphorus, albumin, alkaline phosphatase and parathyroid hormone were retrieved. Hypercalcemia was defined as albumin-corrected calcium >10.5 mg/dL. Among 185 604 results, annual testing increased by 54.1% and median 25(OH)D rose from 25.3 to 28.6 ng/mL. Very high results more than doubled (31 [0.14%] to 108 [0.31%]; n = 393). Calcium was available in 324/393 results, and hypercalcemia occurred in 14/324 (4.3%). Calcifediol was documented in 183/201 (91.0%) hypervitaminosis D patients with available supplementation data and in 12/14 (85.7%) hypercalcemic cases, often in short-interval dosing regimens. Rapid test growth paralleled a rightward shift and expanding high-concentration tail, supporting evidence-based requesting, clearer intermittent-dosing and supplementation instructions, and selective serum calcium surveillance when 25(OH)D is greatly elevated.